Spotlight On Non-Small Cell Lung Cancer
Up to 85 percent of all lung cancer cases are characterized as non-small cell lung cancer, underscoring the importance of keeping up to date on the latest diagnostic and treatment advances. That’s why this Spotlight on Non-Small Cell Lung Cancer brings together leading oncologists and other allied healthcare professionals to discuss key research updates and other novel insights.
31-38 of 38
Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Project Oncology®Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
Project Oncology®Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
Project Oncology®Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
Vivek Subbiah, MD
Recognizing the Role of Capmatinib for METex14 in NSCLC
Project Oncology®Recognizing the Role of Capmatinib for METex14 in NSCLC
Jacob Sands, MD
Edward B. Garon, MD, MS
Checkpoint Inhibitor Combination Therapy for First-Line Advanced NSCLC
Project Oncology®Checkpoint Inhibitor Combination Therapy for First-Line Advanced NSCLC
Jacob Sands, MD
Shirish Gadgeel, MD
Investigating Immunotherapy & Its Role in NSCLC
Project Oncology®Investigating Immunotherapy & Its Role in NSCLC
Jacob Sands, MD
Mark Awad, MD, PhD
- advertisement
Jacob Sands, MD
Mark Awad, MD, PhD
Concerning Kinases: Therapeutic Considerations for RET Rearranged NSCLC
Project Oncology®Concerning Kinases: Therapeutic Considerations for RET Rearranged NSCLC
D. Ross Camidge, MD, PhD
